ESC 2021: EMPEROR-Pooled Shows Consistent Benefits of Empagliflozin on Heart Failure Outcomes in Heart Failure Patients With an Ejection Fraction <65%
The drug may also provide renal protection in patients with lower ejection fractions
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.